Owensmadsen7120
To compare anthropometric and power-related attributes between competition levels in under-19-year-old (U19) male basketball players.
National-level (n = 7; age 17.7 [0.5]y), first-division state-level (n = 8; 17.4 [0.4]y), and second-division state-level (n = 8; 17.1 [0.4]y) players from Australian basketball programs participated in this pilot study. Players had various anthropometric attributes (height, standing reach height, wingspan, and body mass) and power-related attributes (isometric midthigh pull, linear sprint, countermovement jump, 1-step vertical jump, standing long jump, repeated lateral bound, and Modified Agility T Test) measured in the preseason. Differences between groups were assessed using 1-way analyses of variance with Tukey post hoc tests and effect sizes (ES) interpreted as trivial, <0.20; small, 0.20 to 0.59; moderate, 0.60 to 1.19; large, 1.20 to 1.99; and very large, ≥2.00.
Regarding anthropometric attributes, national-level players possessed greater (P < .05, large-veryevels in U19 male basketball players. This information can inform development of testing protocols, reference ranges, and training programs in practice. Further research is encouraged on this topic to confirm our findings across larger samples of basketball players.Tranexamic acid (TXA) is a synthetic lysine analog that reduces perioperative blood loss by blocking lysine-binding sites on plasminogen molecules. It has been reported to be effective in limiting blood loss and transfusion needs in various orthopedic surgeries and for pediatric patients at high risk of blood loss. Randomized controlled trials (RCTs) supporting the capacity of TXA to reduce blood loss and improve outcomes associated with various surgical procedures have increased fourfold in the 10 years since Evidence Corner addressed this topic, which highlighted the capacity of locally delivered TXA to reduce blood loss during orthopedic knee surgery and intravenously delivered TXA to reduce blood lost during elective cesarean sections. Research continues to explore whether the ideal method of TXA delivery is local or systemic. One systemic preoperative 10 mg/kg dose of TXA did not improve blood loss, wound healing, or pain-related outcomes associated with ambulatory foot and ankle surgery. However, repeated topical doses of TXA as well as combined systemic and topical doses improved blood loss, inflammation, and nutritional condition following hip arthroplasty. This installment of Evidence Corner reviews 2 recent studies exploring the effects of adding locally delivered TXA to intravenous (IV) systemic TXA during spinal surgery8 and confirming efficacy of a single dose of topical TXA on hip arthroplasty.
Diabetic foot ulcers (DFUs) are a global burden on health care systems. Despite the availability of various treatment modalities, many DFUs do not heal. Nonhealing wounds can lead to various complications, which add to significant morbidity in terms of the degree of moisture retained in the dressing, pain, foul order, and restriction of daily activities. A different treatment modality that can promote the wound healing process earlier (and is cost-effective, easy to use, and readily available) may be necessary to consider.
The purpose of the current study was to demonstrate the efficacy of ultrathin skin grafting (UTSG) in the early healing of DFUs in terms of cost-effectiveness, reduced total number of hospital visits, and final wound outcome (ie, limb salvage rate).
A randomized controlled trial was conducted in which 52 patients were treated with either UTSG (test group) or conventional dressing (control group). Both groups were compared by time to healing, number of hospital visits, cost, and final outcome of the wound.
By the end of the 12-week study period, 84.61% of wounds managed with UTSG healed completely, whereas only 53.84% of wounds managed with conventional methods achieved complete healing. The test group achieved a more than 50% wound size reduction within 6 weeks after grafting. read more There were fewer hospital visits for the test group, indicating this grafting technique was more cost-effective than the control group.
As demonstrated in this study, UTSG appears to be beneficial in achieving faster healing of DFUs and improving the final outcome of the wound.
As demonstrated in this study, UTSG appears to be beneficial in achieving faster healing of DFUs and improving the final outcome of the wound.
Colonization of a pressure injury with microorganisms can negatively affect wound healing. Thus, it is necessary to evaluate which products best facilitate wound healing.
This case series evaluated the effectiveness of the antimicrobial polyhexamethylene biguanide (PHMB) on microorganisms in pressure injuries.
Fourteen patients (14 wounds) were treated with PHMB in the hospital setting after collection of a wound swab sample for microbiological analysis and determination of the risk profile using the disk diffusion method.
Thirteen lesions (92.9%) were positive for 1 or more bacterial strains, the most prevalent of which were Staphylococcus aureus and Pseudomonas aeruginosa. Two strains of methicillin-resistant S aureus (MRSA) were also identified. Klebsiella pneumoniae demonstrated 100% resistance to the tested antibiotics, with Acinetobacter demonstrating 90% resistance, P aeruginosa 88.9%, Citrobacter freundii 87.5%, S aureus 66.7%, and MRSA 57.1%. Only Serratia marcescens demonstrated no resistance to any antibiotic tested. Polyhexamethylene biguanide was effective only against strains of S marcescens, which were not present in the second wound swab sample collected (after the application of PHMB); other microorganisms were present in the second wound swab sample collected.
Polyhexamethylene biguanide has an immediate antimicrobial effect on S marcescens. However, it had no qualitative effect on the other microorganisms. Studies with larger populations and randomized clinical trial methodologies are necessary to elucidate additional findings concerning the effectiveness of PHMB in managing microorganisms in pressure injuries.
Polyhexamethylene biguanide has an immediate antimicrobial effect on S marcescens. However, it had no qualitative effect on the other microorganisms. Studies with larger populations and randomized clinical trial methodologies are necessary to elucidate additional findings concerning the effectiveness of PHMB in managing microorganisms in pressure injuries.
Augmented reality (AR) is a burgeoning digital technology that is finding more frequent use in health care. The benefits of AR, such as hands-free imaging and remote viewing, make this a tool particularly suited to wound care. To the author's knowledge, no attempts have been made to leverage this technology in a way that might improve patient outcomes. Similarly, few studies on remote wound consultation focus on the inpatient setting.
This study demonstrated the use of AR to improve the outcome of patients undergoing negative pressure wound therapy.
A case-control study of 27 patients treated in a rural Louisiana hospital was performed. A retrospective control group (n = 15) was identified and compared with similar cases (n = 12) that used AR by the bedside nursing staff and an offsite certified wound care clinician.
At univariate analysis, the treatment group was found to have fewer unintended surgical revisions (P =.002), fewer interruptions in therapy time (P =.01), and fewer readmissions related to wound infection (P =.004) compared with the control group. Correlational testing was performed and showed a significant correlation between the number of dressings performed and the number of complications that arose (0.71) as well as between premature dressing removals and number of readmissions related to infection (0.74).
The results of this study, although preliminary, show how AR can be used in the acute care setting to positively influence outcomes of patients undergoing wound care. Further testing is necessary to replicate these findings and assess the use of AR with other advanced modalities or for other indications in the acute care setting.
The results of this study, although preliminary, show how AR can be used in the acute care setting to positively influence outcomes of patients undergoing wound care. Further testing is necessary to replicate these findings and assess the use of AR with other advanced modalities or for other indications in the acute care setting.
Diabetic foot ulcers (DFUs) are a major complication of diabetes. Recently, considerable progress has been achieved in techniques that promote wound healing. Autologous platelet-rich plasma (PRP) is one such technique that is gaining popularity. Platelet-rich plasma is thought to stimulate wound healing by releasing growth factors essential for healing.
This research aimed to study the efficacy of PRP in managing chronic DFUs.
Seventy-two patients with chronic DFUs were equally divided into 2 groups. The first group was treated with activated PRP injection and gel on the surface of the ulcer, and the second group was treated with conventional dressing using normal saline to irrigate the wound, followed by coverage with petrolatum gauze and sterile dressing.
Both methods of treatment improved healing, but there was a significant increase in healing rate among the PRP group compared with the conventional dressing group (31/36 patients [86.11%] vs 23/36 patients [63.89%]; P =.029). Additionally, the healing duration was shorter in the PRP group than in the conventional dressing group (10.90 weeks ± 3.40 standard deviation vs 13.48 weeks ± 3.37, respectively; P =.01).
The use of autologous PRP results in a higher rate of wound healing in less time compared with conventional wound care in managing DFUs. Platelet-rich plasma is an effective and promising treatment for chronic DFUs; PRP enables healing in less time. This is expected to positively affect the individual's performance and minimize long-term health care expenditure on foot ulcers.
The use of autologous PRP results in a higher rate of wound healing in less time compared with conventional wound care in managing DFUs. Platelet-rich plasma is an effective and promising treatment for chronic DFUs; PRP enables healing in less time. This is expected to positively affect the individual's performance and minimize long-term health care expenditure on foot ulcers.
Given the lack of visual discrepancy between malignant and surrounding normal tissue, current breast conserving surgery (BCS) is associated with a high re-excision rate. Due to the increasing cases of BCS, a novel method of complete tumour removal at the initial surgical resection is critically needed in the operating room to help optimize the surgical procedure and to confirm tumour-free edges.
We developed a unique near-infrared (NIR) fluorescence imaging probe, ICG-p28, composed of the clinically nontoxic tumour-targeting peptide p28 and the FDA-approved NIR dye indocyanine green (ICG). ICG-p28 was characterized in vitro and evaluated in multiple breast cancer animal models with appropriate control probes. Our experimental approach with multiple-validations and -blinded procedures was designed to determine whether ICG-p28 can accurately identify tumour margins in mimicked intraoperative settings.
The in vivo kinetics were analysed to optimize settings for potential clinical use. Xenograft tumours stably expressing iRFP as a tumour marker showed significant colocalization with ICG-p28, but not ICG alone.
